Transpharma International

Aalst ·KBO/BCE: BE 0765.495.888

Loading dossier…

Metric	This company	Sector median	Position in the sector
Solvency	39.1%	20.8%	better than 70% of 119 sector peers
Net result	€147k	€19k	better than 78% of 118 sector peers
Equity	€712k	€146k	better than 77% of 119 sector peers
Gross operating margin	€2.18M	€191k	better than 90% of 118 sector peers
Staff costs	€1.83M	€242k	higher than 89% of 73 sector peers

Line item	Code	2024
Balance sheet, Assets
TOTAL ASSETS	20/58	€1.82M
Fixed assets	21/28	€537k
Intangible fixed assets	21	€362k
Tangible fixed assets	22/27	€24k
Financial fixed assets	28	€151k
Current assets	29/58	€1.28M
Amounts receivable within one year	40/41	€1.11M
Cash & bank	54/58	€164k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€1.82M
Equity	10/15	€712k
Contributions / capital	10/11	€1k
Accumulated profits (losses)	14	€711k
Amounts payable	17/49	€1.11M
Amounts payable after one year	17	€109k
Amounts payable within one year	42/48	€853k
Trade debts payable within one year	44	€354k
Income statement
Gross operating margin	9900	€2.18M
Operating result	9901	€245k
Financial income	75	€2k
Financial charges	65	€37k
Result before taxes	9903	€210k
Income taxes	67/77	€63k
Net result for the period	9904	€147k
Result to be appropriated	9905	€147k

Statutory auditor	IRE/IBR number	Tenure
Forvis Mazars Advisory ServicesCurrent Statutory auditor · represented by Koen Potters	-	07-07-2022 → present
Forvis Mazars Réviseurs d’EntreprisesCurrent Statutory auditor · represented by Koen Potters	-	14-10-2022 → present

Summary